Application of the sG8 Scale in Real-World Geriatric Oncology Patients
Launched by SICHUAN CANCER HOSPITAL AND RESEARCH INSTITUTE · Apr 15, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well the sG8 scale, a tool for assessing older patients' health, can be used in real-world settings for those with solid tumors, like breast or lung cancer. The study will include patients aged 65 and older who need treatment for their cancer. Before starting their therapy, these patients will be evaluated using the sG8 scale, but the study will not change their usual treatment plan. The researchers will collect important information about the patients' health and treatment experiences from their medical records during the study.
To be eligible for this trial, patients must be 65 years or older and have a confirmed diagnosis of cancer that requires systemic anti-tumor therapy, meaning they need treatment that affects the whole body, like chemotherapy. They should also be expected to live for at least 12 weeks after joining the study. However, patients who do not meet these criteria or who are unwilling to participate in the health assessment will not be included. Overall, participants can expect their usual treatment to continue while providing valuable information that could help improve care for older cancer patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients aged 65 years or older.
- • 2. Patients with confirmed malignant tumors based on definitive pathological data.
- • 3. Patients who are assessed by clinicians to have indications for systemic anti-tumor therapy.
- • 4. Patients with a survival time greater than 12 weeks.
- Exclusion Criteria:
- • 1. Patients who do not meet the above inclusion criteria or are considered unsuitable for this study by the investigator due to other circumstances.
- • 2. Patients who are unwilling to cooperate in completing the sG8 scale assessment.
- • 3. Patients who do not understand the content of this study or are unwilling to participate.
About Sichuan Cancer Hospital And Research Institute
Sichuan Cancer Hospital and Research Institute is a leading comprehensive cancer treatment and research facility located in Chengdu, China. Renowned for its commitment to advancing oncology, the institute integrates clinical practice with cutting-edge research to develop innovative treatment protocols and enhance patient care. With a multidisciplinary team of experts, the hospital focuses on a wide range of cancer therapies, including surgical, medical, and radiation oncology, while also actively participating in clinical trials to contribute to the global understanding of cancer management. Its state-of-the-art facilities and dedication to research make it a pivotal player in the fight against cancer in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported